NRIX
Nurix Therapeutics, Inc.NASDAQHealthcare$15.51+0.19%ClosedMarket Cap: $1.34B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.79
P/S
16.30
EV/EBITDA
-4.58
DCF Value
$-33.31
FCF Yield
-19.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-87.4%
Operating Margin
-340.2%
Net Margin
-314.9%
ROE
-57.5%
ROA
-38.4%
ROIC
-47.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $13.6M | 65.9% | $-83.1M | $-78.2M | $-0.82 | — |
| FY 2025 | $84.0M | 77.5% | $-285.7M | $-264.5M | $-3.05 | — |
| Q3 2025 | $7.9M | 36.7% | $-91.4M | $-86.4M | $-1.03 | — |
| Q2 2025 | $44.1M | -77.3% | $-48.3M | $-43.5M | $-0.52 | — |
| Q1 2025 | $18.5M | -277.5% | $-62.9M | $-56.4M | $-0.67 | — |
| Q4 2024 | $13.3M | -406.1% | $-64.7M | $-58.5M | $-0.75 | — |
| FY 2024 | $54.5M | -306.3% | $-213.0M | $-193.6M | $-2.88 | — |
| Q3 2024 | $12.6M | -340.7% | $-54.6M | $-49.0M | $-0.67 | — |
| Q2 2024 | $12.1M | -304.6% | $-48.5M | $-44.5M | $-0.71 | — |
| Q1 2024 | $16.6M | -201.5% | $-45.2M | $-41.5M | $-0.76 | — |
| Q4 2023 | $15.2M | -227.9% | $-45.3M | $-42.0M | $-0.77 | — |
| FY 2023 | $77.0M | -145.7% | $-155.1M | $-143.9M | $-2.65 | — |